Ascletis Oral GLP-1 ASC30 Hits Phase II Diabetes Endpoint as Phase III Obesity Program Advances
Ascletis Pharma (HKEX: 1672) reported that its oral GLP-1 receptor agonist ASC30 met the primary endpoint in a Phase II type 2 diabetes trial, with placebo-adjusted HbA1c reductions of 1.7%, 1.6% and 1.7% at 40 mg, 60 mg and 80 mg respectively at 12 weeks. The readout extends the investigational drug’s clinical profile beyond obesity into type 2 diabetes, while the same molecule continues through a global Phase III obesity program launched in August 2026.
For the peptide therapy and research peptide industry, the result matters less as a single data point than as a signal about the direction of oral GLP-1 development. Every oral GLP-1 candidate that clears a mid-stage efficacy bar adds pressure on injectable incumbents, reshapes how clinics and telehealth operators think about patient onboarding, and raises new questions about formulation, fill-finish capacity and the supply chains that sit behind both oral tablets and injectable vials and pens.
What Ascletis reported in the Phase II diabetes trial
According to the company’s topline announcement, ASC30 — an oral GLP-1 receptor agonist developed by Ascletis Pharma — met its primary endpoint in a Phase II study in type 2 diabetes. Placebo-adjusted HbA1c reductions at 12 weeks, calculated using least squares mean, were 1.7% for the 40 mg dose (n=20), 1.6% for the 60 mg dose (n=29) and 1.7% for the 80 mg dose (n=28). The primary comparison against placebo returned p < 0.0001 in an efficacy analysis of 77 participants whose mean baseline HbA1c was 8.3%.
The company also reported that ASC30 met all secondary endpoints, including placebo-adjusted body weight reductions of 3.8%–4.4% at 13 weeks (p = 0.001 to 0.003). On safety, Ascletis stated that no study discontinuations due to gastrointestinal adverse events occurred in the ASC30 maintenance-dose groups, that all drug-related adverse events were Grade 1 or Grade 2, and that there were no drug-related serious adverse events.
Two limitations should be stated plainly. First, the results are topline and confidence intervals were not reported, which means the precision of the effect estimates cannot be assessed from the announcement alone. Second, the efficacy analysis covered 77 participants across three dose arms over a 12- to 13-week window — a design suited to detecting a signal, not to characterising long-term glycaemic control, tolerability in broader populations, or durability after treatment stops.
Key numbers at a glance
| Measure | Result reported by Ascletis | Population / timing |
|---|---|---|
| Placebo-adjusted HbA1c reduction, 40 mg | 1.7% | n=20; 12 weeks |
| Placebo-adjusted HbA1c reduction, 60 mg | 1.6% | n=29; 12 weeks |
| Placebo-adjusted HbA1c reduction, 80 mg | 1.7% | n=28; 12 weeks |
| Primary comparison vs placebo | p < 0.0001 | Efficacy analysis, 77 participants |
| Mean baseline HbA1c | 8.3% | Efficacy analysis population |
| Placebo-adjusted body weight reduction | 3.8%–4.4% (p = 0.001 to 0.003) | 13 weeks |
| Phase III obesity enrolment target | ~4,600 participants | AURORA-1 and AURORA-2; US, Europe, Canada |
| Phase III topline / FDA NDA target | Q3 2028 / end of 2028 | Company forecast |
Why the readout matters for peptide therapy and GLP-1 research
GLP-1 receptor agonists are peptides, and the class has become the single largest commercial driver in peptide manufacturing over the past several years. Semaglutide and tirzepatide — the latter acting on both GIP and GLP-1 receptors — established the metabolic category, and their approved products, indications, dosing and labelling differ in ways that matter clinically. ASC30 sits in the same mechanistic family but takes a different delivery route: oral administration rather than subcutaneous injection.
That distinction is commercially significant. Oral GLP-1 therapy, if it survives Phase III, would compete for the same patients as injectables while bypassing the vial-and-pen supply chain entirely, shifting demand toward tablet fill-finish, oral formulation excipients and different stability requirements. Industry observers note that this does not eliminate injectable demand — obesity and diabetes prevalence is far too large — but it could fragment the market in ways that change how clinics stock, prescribe and counsel patients.
For research peptide suppliers and laboratories, oral GLP-1 programs also change the analytical agenda. Oral peptides face distinct challenges around enzymatic degradation, permeability enhancement and content uniformity, which place greater weight on impurity profiling, assay content measurement and batch-to-batch consistency than on the chromatographic purity figure alone. A certificate of analysis reports specified analytical results for a material or batch; it does not by itself establish clinical safety, efficacy or suitability for human administration.
What the evidence does and does not establish
The Phase II data support a narrow, defensible conclusion: in a 77-participant efficacy analysis with a mean baseline HbA1c of 8.3%, three ASC30 dose groups produced placebo-adjusted HbA1c reductions of 1.6%–1.7% at 12 weeks with p < 0.0001 for the primary comparison, alongside placebo-adjusted weight reductions of 3.8%–4.4% at 13 weeks.
The evidence does not establish that these effects generalise to wider or longer-treated populations, that the gastrointestinal tolerability profile will hold at scale, or that the Phase III obesity program will read out on schedule. The Phase III timeline — topline results expected in Q3 2028 and a US FDA New Drug Application submission targeted by the end of 2028 — is a company forecast, not an observed event. Enrolment delays, protocol amendments or regulatory feedback could all move those dates.
It is also worth being precise about sequencing. Ascletis initiated the global Phase III obesity program in August 2026, before this diabetes readout was reported. The available material does not state that the Phase II diabetes result triggered or shaped the Phase III decision, and readers should not infer that causal link.
Supply chain and clinic implications
The Phase III program, comprising the AURORA-1 and AURORA-2 trials, is expected to enrol approximately 4,600 participants across the US, Europe and Canada. A study of that size implies sustained demand for clinical trial supply: peptide active pharmaceutical ingredient manufactured under appropriate controls, finished investigational product in the relevant dosage form, comparator and placebo supply, blinded labelling, and temperature-controlled distribution across three regions.
This is where supply-chain visibility becomes an operational issue rather than an abstract one. Buyers evaluating peptide API and finished-product partners typically need batch-level certificates of analysis, product specifications, analytical method information, impurity profiles, stability data and manufacturing-site traceability — a documentation package that should match the product’s intended market and stage of development. For organisations tracking these flows, peptidescm maintains industry coverage of peptide supply chains, while PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
For peptide therapy clinics and telehealth operators in the US, the near-term effect of this readout is indirect. ASC30 is investigational and is not an approved medicine; it cannot be prescribed, dispensed or offered as a treatment. Clinics should continue to distinguish carefully between FDA-approved GLP-1 medicines, compounded drugs prepared under specific legal conditions, and research-use-only materials, which are intended for laboratory work and should not be represented as human medicines. Any GLP-1 therapy decision belongs with a licensed prescriber and appropriate medical supervision.
What to watch next
- Full Phase II disclosure. Peer-reviewed publication or conference presentation with confidence intervals, per-protocol details and the full adverse-event table would allow independent assessment of the effect size.
- AURORA-1 and AURORA-2 enrolment pace. Recruitment progress across the US, Europe and Canada is the leading indicator for whether the Q3 2028 topline target holds.
- Oral-versus-injectable competitive dynamics. How injectable GLP-1 manufacturers and compounding stakeholders respond to oral entrants will shape clinic formularies and patient counselling.
- Regulatory signals. Any FDA interaction disclosed by Ascletis ahead of a planned New Drug Application submission would clarify the evidentiary package regulators expect for an oral GLP-1 peptide.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. It was compiled from publicly available information together with a news lead provided by Sarah, a business manager at PeptideDDP; the original information originated from PeptideDDP.com.
Frequently asked questions
Did ASC30 meet its Phase II diabetes endpoint?
Yes, according to Ascletis. The company reported that ASC30 met the primary endpoint, with placebo-adjusted HbA1c reductions at 12 weeks of 1.7% (40 mg), 1.6% (60 mg) and 1.7% (80 mg) and p < 0.0001 for the primary comparison in an efficacy analysis of 77 participants.
Is ASC30 an approved treatment for diabetes or obesity?
No. ASC30 is an investigational oral GLP-1 receptor agonist. It has not been approved for any indication, and the Phase III obesity program is ongoing with topline results expected in Q3 2028 according to the company.
What were the safety findings in the Phase II trial?
Ascletis reported no study discontinuations due to gastrointestinal adverse events in the ASC30 maintenance-dose groups, all drug-related adverse events being Grade 1 or Grade 2, and no drug-related serious adverse events. These are topline company-reported findings from a limited population.
How does an oral GLP-1 differ from injectable GLP-1 medicines?
Both act on the GLP-1 receptor, but oral administration avoids the vial-and-pen delivery chain and imposes different formulation and stability requirements. Approved injectable products such as semaglutide and tirzepatide have their own labelled indications, dosing and contraindications that should be checked individually.
Can clinics offer ASC30 to patients now?
No. ASC30 is not approved and is not available as a treatment. Clinics should rely on approved medicines prescribed under medical supervision and should not substitute research-use-only peptides for approved therapies.